Blood Reviews最新文献_第4页

MRD in multiple myeloma: Moving from “minimal” to “measurable” 多发性骨髓瘤的MRD：从“最小”到“可测量”。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-06-20 DOI: 10.1016/j.blre.2026.101413

Raffaella Cassano Cassano, Rahul Banerjee, Aimaz Afrough, Andrew J. Portuguese, Richa Thakur, Kara Cicero, Mary Kwok, Laahn Foster, Gabriele Buda, Silviya Meletath, Sara Galimberti, Gaetano Serviddio, Madhav V. Dhodapkar, Danai Dima

{"title":"MRD in multiple myeloma: Moving from “minimal” to “measurable”","authors":"Raffaella Cassano Cassano, Rahul Banerjee, Aimaz Afrough, Andrew J. Portuguese, Richa Thakur, Kara Cicero, Mary Kwok, Laahn Foster, Gabriele Buda, Silviya Meletath, Sara Galimberti, Gaetano Serviddio, Madhav V. Dhodapkar, Danai Dima","doi":"10.1016/j.blre.2026.101413","DOIUrl":"10.1016/j.blre.2026.101413","url":null,"abstract":"<div><div>The assessment of <em>minimal</em> residual disease (MRD) is an important prognostic factor in hematologic malignancies, including multiple myeloma (MM). Historically defined as cancer cells undetectable by conventional morphology, MRD is now more appropriately termed measurable residual disease, reflecting its quantitative and clinically actionable nature. Advances in next-generation flow cytometry and next-generation sequencing have enabled detection of disease at sensitivities as low as 10<sup>−6</sup> and even 10<sup>−7</sup>, redefining the concept of complete response. Nonetheless, challenges remain regarding assay sensitivity, standardization, and interpretation of results. Achieving MRD-negativity is a strong and independent predictor of improved survival outcomes in both newly diagnosed and relapsed/refractory MM. Consequently, MRD negativity has increasingly been accepted by regulatory agencies as an intermediate endpoint supporting accelerated drug approval. This review summarizes MRD detection methodologies, clinically relevant thresholds, and therapeutic implications, highlighting the paradigm shift from “<em>minimal</em>” to measurable residual disease.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101413"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet biology and etiopathogenesis of congenital platelet disorders 血小板生物学和先天性血小板疾病的发病机制。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-05-22 DOI: 10.1016/j.blre.2026.101399

Ana C. Glembotsky, Nora V. Butta, José M. Bastida, José Rivera

引用次数: 0

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review 原发性皮肤t细胞淋巴瘤（蕈样真菌病和ssamzary综合征）：一项基于室的实用综述。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-04-24 DOI: 10.1016/j.blre.2026.101393

Pablo Mozas, Andrea Combalia, Gabriela Antelo, Irene López-Oreja, Natalia Castrejón de Anta, Inés Monge-Escartín, Deborah Moreno-Alonso, Javier Gil-Lianes, Minerva Juncosa, María Queralt Salas, Paola Charry, Robert Albero, Adriana García-Herrera, Armando López Guillermo, Teresa Estrach

{"title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review","authors":"Pablo Mozas, Andrea Combalia, Gabriela Antelo, Irene López-Oreja, Natalia Castrejón de Anta, Inés Monge-Escartín, Deborah Moreno-Alonso, Javier Gil-Lianes, Minerva Juncosa, María Queralt Salas, Paola Charry, Robert Albero, Adriana García-Herrera, Armando López Guillermo, Teresa Estrach","doi":"10.1016/j.blre.2026.101393","DOIUrl":"10.1016/j.blre.2026.101393","url":null,"abstract":"<div><div>Primary cutaneous lymphomas are a heterogeneous group of lymphoid neoplasms with predominant skin involvement, among which mycosis fungoides (MF) and Sézary syndrome (SS) are the most frequent and clinically challenging entities. This narrative review provides a multidisciplinary, compartment-oriented approach to the diagnosis, staging and management of MF/SS. We summarize the therapeutic principles across the disease continuum, from early-stage, skin-directed management to advanced-stage systemic therapy, including oral retinoids, methotrexate, extracorporeal photopheresis, mogamulizumab, brentuximab vedotin, chemotherapy and allogeneic stem-cell transplantation. We also address large-cell transformation, response assessment, follow-up strategies, and practical issues surrounding treatment maintenance, spacing and discontinuation in a chronic, relapsing disease. Finally, we highlight the importance of supportive care, particularly pruritus control and palliative integration when no further effective options remain, and provide pragmatic algorithms to facilitate real-world clinical decision-making.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101393"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147790422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI for the assessment and discovery of morphological–molecular biomarker relationships in hematologic malignancies 用于评估和发现血液学恶性肿瘤中形态-分子生物标志物关系的人工智能。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 Epub Date: 2026-05-26 DOI: 10.1016/j.blre.2026.101398

Ignacio Hernández-Abad, Raquel Ancos-Pintado, Ana Mendoza, Álvaro Basterra-García, Roberto García-Vicente, Juan E. Ortuño, Alba Rodríguez-García, Alejandra Ortiz-Ruiz, Nuria Díez, David Bermejo-Peláez, David Brau-Queralt, Irene Zamanillo, Paula Sánchez-Llorca, Andrés Santos, Joaquín Martínez-López, Miguel Luengo-Oroz, María Hernández-Sánchez, María Linares, María J. Ledesma-Carbayo

{"title":"AI for the assessment and discovery of morphological–molecular biomarker relationships in hematologic malignancies","authors":"Ignacio Hernández-Abad, Raquel Ancos-Pintado, Ana Mendoza, Álvaro Basterra-García, Roberto García-Vicente, Juan E. Ortuño, Alba Rodríguez-García, Alejandra Ortiz-Ruiz, Nuria Díez, David Bermejo-Peláez, David Brau-Queralt, Irene Zamanillo, Paula Sánchez-Llorca, Andrés Santos, Joaquín Martínez-López, Miguel Luengo-Oroz, María Hernández-Sánchez, María Linares, María J. Ledesma-Carbayo","doi":"10.1016/j.blre.2026.101398","DOIUrl":"10.1016/j.blre.2026.101398","url":null,"abstract":"<div><div>Artificial intelligence (AI) is transforming morphological assessment in hematologic malignancies by enabling automated cell classification, detection of disease-specific features, and prediction of genetic alterations from blood and bone marrow smear images. Deep learning models have achieved expert-level performance in identifying malignant patterns, uncovering morphologic–molecular associations, and providing patient-level diagnoses through multiple instance learning approaches. This review summarizes recent advances in AI-driven morphological analysis across myeloid and lymphoid neoplasms, emphasizing their impact on diagnosis and disease classification. We further examine emerging evidence linking image-derived features, such as nuclear texture, cytoplasmic granularity, and spatial cell organization, to molecular and prognostic variables. In addition, we discuss enabling technologies, including virtual staining and interpretability methods, that support clinical integration. Finally, we address key challenges, including data heterogeneity, the need for prospective validation, and interdisciplinary collaboration. AI-powered, explainable morphological analysis has the potential to advance precision hematology and personalized patient management.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"77 ","pages":"Article 101398"},"PeriodicalIF":7.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A tale of two sites – Distinct spatial differences between bone marrow and extramedullary AML 两个部位的故事-骨髓和髓外AML的明显空间差异。

IF 7.2 2区医学

Blood Reviews Pub Date : 2026-07-01 DOI: 10.1016/j.blre.2026.101416

Hossein Emami, Annette I. Garbe, Karin Huber, Friedrich Stölzel, Julia Frimmel

引用次数: 0

The gut microbiome in B cell lymphoma B细胞淋巴瘤的肠道微生物组。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2025-12-09 DOI: 10.1016/j.blre.2025.101357

Darcy Vickers , Arina Martynchyk , Andrea Henden , Olivia C. Smibert , Eliza A. Hawkes , Geoff Chong

引用次数: 0

Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets 多发性骨髓瘤和髓外疾病的代谢改变——一个新的治疗靶点

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2025-12-22 DOI: 10.1016/j.blre.2025.101360

Ellen Purcell , Paul Dowling , Peter O’Gorman , Despina Bazou

引用次数: 0

CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access CAR-T适用于所有人？CAR - t细胞商业化治疗的障碍、促进因素和干预措施。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2025-12-16 DOI: 10.1016/j.blre.2025.101358

Sofia Kaparis , Khashayar Eshaghi , Luca Paruzzo , Jalpa Doshi , Marco Ruella , Carmen E. Guerra

{"title":"CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access","authors":"Sofia Kaparis , Khashayar Eshaghi , Luca Paruzzo , Jalpa Doshi , Marco Ruella , Carmen E. Guerra","doi":"10.1016/j.blre.2025.101358","DOIUrl":"10.1016/j.blre.2025.101358","url":null,"abstract":"<div><div>Chimeric antigen receptor T-cell (CAR-T) immunotherapy has revolutionized the treatment of hematologic malignancies, especially in B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, and multiple myeloma. However, inequitable access to CAR T-cell immunotherapy has been demonstrated among racial and ethnic minority populations. This scoping review examined 37 works of published literature on barriers and facilitators to accessing commercial CAR-T therapy, as well as interventions to mitigate access inequities. The results are organized using the socio-ecological model across patient, provider, institutional, and policy levels, and highlight how these barriers and facilitators can disproportionately affect racial and ethnic minority populations. Barriers are complex and present at all socio-ecological levels, and only two published interventions that target minority access disparities to CAR-T therapy were identified. Key research gaps, including the limited number of barriers supported by objective, primary data and the absence of patient-identified barriers, are discussed. Collectively, the barriers, facilitators, and interventions identified in this scoping review can inform comprehensive, multilevel strategies to eliminate access inequities to commercial CAR T-cell immunotherapy.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101358"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guideline-based diagnosis and management of congenital platelet function disorders: Current insights and future directions 基于指南的先天性血小板功能障碍的诊断和管理：当前的见解和未来的方向。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-03-11 DOI: 10.1016/j.blre.2026.101386

Stavroula Parastatidou , Rozeta Sokou , Alexandra Lianou , Konstantina A. Tsante , Efstathia-Danai Bikouli , Eleni Petrou , Sotirios P. Fortis , Deny Tsakri , Marianna Vlachaki , Vasileios Petrakis , Eleni Gavriilaki , Styliani Kokoris , Stefanos Bonovas , Andreas G. Tsantes

{"title":"Guideline-based diagnosis and management of congenital platelet function disorders: Current insights and future directions","authors":"Stavroula Parastatidou , Rozeta Sokou , Alexandra Lianou , Konstantina A. Tsante , Efstathia-Danai Bikouli , Eleni Petrou , Sotirios P. Fortis , Deny Tsakri , Marianna Vlachaki , Vasileios Petrakis , Eleni Gavriilaki , Styliani Kokoris , Stefanos Bonovas , Andreas G. Tsantes","doi":"10.1016/j.blre.2026.101386","DOIUrl":"10.1016/j.blre.2026.101386","url":null,"abstract":"<div><div>Congenital platelet function disorders constitute a heterogeneous group of rare, genetic conditions classified according to the affected platelet component or functionality. Sixty entities have been identified, caused by defects in around seventy-five different genes. Clinical manifestations vary, ranging from asymptomatic to life-threatening. Patients typically present with spontaneous mucocutaneous hemorrhage, but syndromic conditions and malignancy risk are sometimes associated with inherited platelet function disorders. Early and accurate diagnosis, and long-term follow-up of the affected individuals by a multidisciplinary team of experts is crucial. Guidelines on laboratory testing have been developed. The initial approach consists of a comprehensive personal and family history and thorough examination. Diagnostic workup includes complete blood count, peripheral blood smear, light-transmission aggregometry, flow cytometry, electron microscopy, and genetic analysis. Stepwise diagnostic algorithms have been suggested, optimizing the diagnosis and care of patients presenting with clinical symptoms typical for congenital platelet function disorders. Further advancement and wider access to more recent diagnostic technologies are key to providing optimal personalized management and therapy. The future will entail earlier application of genomics, diagnostic tools enhanced by artificial intelligence, international collaborative networks and streamlined diagnostic models.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101386"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives Avatrombopag在免疫性血小板减少症及其他疾病中的应用：目前的证据和新兴的观点。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2025-12-28 DOI: 10.1016/j.blre.2025.101361

María Luisa Lozano , Michele P. Lambert , Hanny Al-Samkari

引用次数: 0